SCHEMBL4763006

SCHEMBL4763006

Cc1c(C(=O)NC(CC(C)C)C(=O)N([C@H]2CCCNCC2=O)S(=O)(=O)C2=NC=CCC2=O)oc2ccccc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.36
RAB9A P51151 8/20 0.36
CAPN1 P07384 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
KMT2A Q03164 1/20 0.33
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
NFKB1 P19838 1/20 0.32
CASP1 P29466 1/20 0.32
HTT P42858 1/20 0.32
CASP7 P55210 1/20 0.32
NFKB2 Q00653 1/20 0.32
RELA Q04206 1/20 0.32
HSD17B10 Q99714 1/20 0.32
FPR1 P21462 1/20 0.32
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4766746 0.92 CAPN1 (0.34) CAPN1L3MBTL1ALDH1A1KMT2ALMNA
SCHEMBL6590220 0.92 RAB9A (0.38) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL6588766 0.90 CTSK (0.32)
SCHEMBL4768504 0.89 MMP2 (0.33)
SCHEMBL4765494 0.86 CTSK (0.40) NPC1RAB9ASMN1; SMN2
SCHEMBL4763179 0.86 NPC1 (0.35) NPC1RAB9ACAPN1SMN1; SMN2L3MBTL1
SCHEMBL4825088 0.86 L3MBTL1 (0.39) NPC1RAB9ACAPN1SMN1; SMN2L3MBTL1
SCHEMBL4770541 0.86 NPC1 (0.36) NPC1RAB9ACAPN1SMN1; SMN2L3MBTL1
SCHEMBL4768763 0.86 RXFP1 (0.37) NPC1RAB9ACAPN1SMN1; SMN2L3MBTL1
SCHEMBL4825080 0.86 L3MBTL1 (0.39) NPC1RAB9ACAPN1SMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1320370-A4 METHOD OF TREATMENT SMITHKLINE BEECHAM CORP (US) 2008-10-22 EP disclosed
EP-1320370-A1 METHOD OF TREATMENT SmithKline Beecham Corporation (US) 2003-06-25 EP disclosed
WO-2002017924-A1 METHOD OF TREATMENT SMITHKLINE BEECHAM CORPORATION (GB) 2002-03-07 WO disclosed